
GLP-1 and Intermittent Fasting 2026: When Combining Helps, When It Backfires
Should you do IF on Ozempic, Wegovy, or Mounjaro? Hypoglycemia risk, muscle loss, and an electrolyte protocol that protects results.
Articles
Clinical-trial-grounded articles on GLP-1, peptide, and metabolic medications — what's prescribed today, what's coming next, and how to make sense of the science.

Should you do IF on Ozempic, Wegovy, or Mounjaro? Hypoglycemia risk, muscle loss, and an electrolyte protocol that protects results.

Stacking keto with Ozempic, Wegovy, or Mounjaro? Keto-flu meets GLP-1 nausea, muscle preservation, and the keto-rebound risk when titrating off.

Foundayo (orforglipron) FDA approved April 1, 2026 — the first oral GLP-1 pill with no food restrictions. Cost, efficacy, side effects, drug interactions.

Mounjaro, Zepbound, and Foundayo all warn that oral birth control may fail. Safe contraceptive options and exactly how long backup is needed.

GLP-1 users move 11% less per ENDO 2026 data. Resistance training, protein, and ketone ester protocol that preserves 92% of muscle mass.

What clinical trials show happens when you stop GLP-1s — STEP 1 Extension, SURMOUNT-4, and the 2026 meta-analysis — plus a safer off-ramp.

A complete look at the Phase 2 NEJM data (24.2% mean weight loss) and the May 2026 TRIUMPH-1 Phase 3 topline (28.3% at 80 weeks). What the responder rates and unreached plateau actually mean.

The mechanism behind the next generation of metabolic drugs. Why adding glucagon to GLP-1 and GIP increases energy expenditure, not just appetite suppression — and what it means for tolerability and safety.

Lilly's confirmed Q4 2026 NDA filing intent, the TRIUMPH Phase 3 readout schedule, and three realistic FDA decision scenarios ranging from mid-2027 to early 2028.

Side-by-side Phase 2 vs. TRIUMPH-1 Phase 3 dose-escalation schedules, the rationale for the added 6 mg step, and how retatrutide titration compares to tirzepatide and semaglutide.

Why the right Mounjaro comparator is SURMOUNT-1 (obesity) and not SURPASS (T2D), and what the TRIUMPH-5 head-to-head trial will settle by late 2026.

A methodologically rigorous cross-trial comparison of SURMOUNT-1 (tirzepatide, 20.9%) and TRIUMPH-1 (retatrutide, 28.3%) — plus what each methodological difference can and can't explain.

How to meet protein targets when appetite is suppressed on Ozempic or Wegovy. Sample meal patterns, practical tips, and why protein protects muscle.

An honest, evidence-based guide to peptides marketed for fat loss — AOD-9604, tesamorelin, BPC-157, and others — including what evidence exists, legal status, and consumer warnings.

Ozempic and Wegovy are the same molecule — semaglutide — but with key differences in approved dose, indication, insurance, and cost. Here's the full breakdown.

Plain-English guide to next-gen weight loss drugs in late-stage trials: retatrutide, survodutide, cagrisema — what they are, how they work, and what the data shows.

Mounjaro and Zepbound are the same drug — tirzepatide — in different packaging. Here's what determines which you get, and how costs differ.

Evidence-based strategies for managing GLP-1 side effects including nausea, fatigue, constipation, and sulfur burps on Ozempic, Wegovy, or Mounjaro.

Plain-English breakdown of STEP, SURMOUNT, and SCALE trial data — what average weight loss on Wegovy, Mounjaro, and Ozempic looks like in the real world.

Why weight loss plateaus happen on Ozempic, Wegovy, and Mounjaro — the biology behind them, when to expect one, and evidence-based strategies to move forward.

GLP-1 suppresses appetite and drives weight loss. GLP-2 is a gut growth hormone for short bowel syndrome. Learn why GLP-2 is not a weight loss therapy — and what's actually true.

A complete guide to GLP-1 dose escalation — why slow titration exists, what happens at each step on Wegovy, Ozempic, Zepbound, and when to ask about pausing.

Full 2026 breakdown of GLP-1 medication costs with and without insurance — Ozempic, Wegovy, Mounjaro, Zepbound — plus savings cards, GoodRx, and compounding options.

A week-by-week guide to your first month on Ozempic, Wegovy, or Mounjaro — appetite changes, side effects, and what's normal.

How to set calorie and macro targets on Ozempic, Wegovy, or Mounjaro. Why extreme undereating backfires, muscle loss risks, and a practical nutrition framework.

A complete guide to compounded semaglutide and tirzepatide — legal status in 2026, FDA stance, safety differences vs. branded drugs, cost comparison, and what to watch for.

CagriSema Phase 3 data explained — how combining semaglutide with the amylin analog cagrilintide produced 22.7% weight loss, and why amylin matters for obesity treatment.